480p * phase ii, multicenter, open-label, proof of concept study of tasquinimod in patients with advanced hepatocellular (hcc), ovarian (oc), renal cell (rcc) and gastric (gc) carcinomas

Conclusions: The data did not support further development of tasquinimod mono therapy in heavily pretreated patients with OC, RCC and GC. Pharmacokinetic and biomarkers analyses are ongoing.HCC cohort is continuing with results expected 2015.Pili R et al, J Clin Oncol. 2011; 29:4022-8.Escudier B et al, J Clin Oncol. 2013;31(abstract TPS2622).Disclosure: R. Plummer: Ipsen funding to institution for present study; I.B. Vergote: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Eisai, Eli Lilly, GE, GSK, Ipsen, Janssen, Menarini, MSD, Novartis, Novo Nordisk, Pfizer, Quintiles, Roche, Sanofi, Sandoz, Shering-Plough, Vifor, Wyett; R.J. Jones: Ipsen research funding GSK research funding, speaker honoraria, advisory board Pfizer research funding, speaker honoraria, advisory board Novartis research funding, speaker honoraria, advisory board Roche research funding; E. Van Cutsem: Ipsen funding to institution for present study; S. Faivre: Ipsen: research funding, advisory board; C. Descot: Ipsen employee; N. Germann: Ipsen employee. All other authors have declared no conflicts of interest.

Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Oza, A. M., Plummer, R., Vergote, I. B., Thistlethwaite, F., Bjarnason, G. A., Jones, R. J., Mackay, H., Van Cutsem, E., Faivre, S., Descot, C., Germann, N., Escudier, B. Tags: developmental therapeutics Source Type: research